Month: August 2023

WEST COLUMBIA, S.C. – Nephron Pharmaceuticals Corporation welcomed Morgan Nichols Scarnecchia as its Chief of Staff. In her new role, Scarnecchia will implement strategic business initiatives, manage daily operations and work alongside CEO, Lou Kennedy, in internal and external affairs.

“As two women who grew up in Lexington, Morgan and I not only share a great passion for the life sciences, but also South Carolina and the Midlands,” said Nephron CEO and Owner Lou Kennedy. “She is a great addition to our strong female leadership here at Nephron – and by working together, we will continue to drive Nephron forward.”

Before joining the Nephron team, Scarnecchia was the Director of Corporate Affairs for KOR Medical, where she built and managed the start-up’s key corporate accounts and communications for its various entities.

Scarnecchia has served as Corporate Affairs and Investor Relations Manager at SCbio, where she was responsible for board and investor communications and leading life sciences workforce initiatives like the association’s K-12 education programs. She began her career at the biotechnology organization as its Membership and Marketing Coordinator, recruiting life science companies and implementing new stakeholder engagement strategies.

In 2019, Scarnecchia was crowned Miss South Carolina. During her reign, she traveled across South Carolina promoting Stronger With STEM, a personal initiative created to promote a 21^st century workforce in the areas of science, technology, engineering and mathematics.

Scarnecchia received a Bachelor of Science in Genetics from Clemson University and is currently pursuing her Master of Biotechnology and Business from Johns Hopkins University.

A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products. The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes, luer-lock vials, IV bottles and IV bags for hospitals across America, in an effort to alleviate drug shortage needs. For more information, please visit www.nephronpharm.com.

 

-###-

WEST COLUMBIA, S.C. – Nephron Pharmaceuticals Corporation today announced Julie Rameas as Chief Procurement Officer. In her new role, Rameas will oversee all strategic sourcing and procurement activities.

“We could not be more excited to welcome Julie to the team. Her rock star resume and body of work speaks for itself,” said Nephron CEO and Owner Lou Kennedy. “From leading manufacturers to global success to blazing trails in textiles, Julie is precisely the kind of professional, who will help lead the continued growth and expansion of our company, and that is a great thing for those who depend on Nephron for life-saving medications.”

Rameas is an experienced professional with proven success in the pharmaceutical, medical device, metal, electronic, aerospace, automotive, and textile manufacturing industries.

Before joining the Nephron team, Rameas served as Senior Director of Global Strategic Procurement at Thermo Fisher Scientific, where she led spending activities for over 800 global sites, and managed multiple global expansion and construction projects.

She has held key global director roles at Lear Corporation, managing all aspects of global strategic procurement activity for seven manufacturing sites, and BioMerieux, where she led spending on all chemicals, biologics and controlled substances.

Rameas received her Bachelor of Science in chemistry from Indiana University of Pennsylvania.

A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products. The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes, luer-lock vials, IV bottles and IV bags for hospitals across America, in an effort to alleviate drug shortage needs. For more information, please visit www.nephronpharm.com.

-###-

WEST COLUMBIA, S.C. – Nephron 503B Outsourcing Facility, a division of Nephron Pharmaceuticals Corporation, is focused on resolving drug shortage concerns with the production of 0.5% Albuterol 5 mL, del Nido Cardioplegia, Lidocaine 1% and Succinylcholine products.

The following medications are readily available for order through the Nephron online ordering portal:

– 0.5% Albuterol 25 mg/5 mL (5 mg/mL) Preservative Free

– del Nido Cardioplegia Solution 1000 mL

– Lidocaine Injection Vial, USP 1% 50 mg/5 mL (10 mg/mL) Preservative Free

– Succinylcholine Chloride Injection, USP 200 mg/10 mL (20 mg/mL) Preservative Free

“As a nationwide leader in manufacturing lifesaving medication, we work hard every single day to help the federal government alleviate drug shortages – and to deliver hospitals and patients the treatments they deserve and expect in a timely manner,” said Lou Kennedy, CEO and Owner of Nephron. “Playing this vital role in manufacturing is all the motivation we need to do our jobs well – and stay focused on precisely what it takes to raise the bar not only for our team, but for manufacturers everywhere.”

Nephron has over 25 years of sterile pharmaceutical manufacturing experience and operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes, luer-lock vials, IV bottles and IV bags for hospitals across America.

To place an order, customers can contact Nephron directly at NOFaccounts@nephronpharm.com or 1-844-224-2225.